Soligenix Inc. (NASDAQ: SNGX) has reported third quarter 2025 financial results while highlighting significant clinical progress across its rare disease treatment pipeline. The company maintains $10.5 million in cash as of September 30, 2025, providing an operating runway expected to extend through 2026 as it evaluates strategic options to advance its late-stage development programs.
The company's Specialized BioTherapeutics business segment is advancing multiple clinical programs, with CEO Christopher J. Schaber, PhD confirming that the first Data Monitoring Committee review found no safety concerns for HyBryte™ (SGX301), maintaining a consistent safety profile across trials. This synthetic hypericin sodium treatment represents a novel photodynamic therapy utilizing safe visible light for cutaneous T-cell lymphoma (CTCL). With successful completion of the second Phase 3 study, the company will seek regulatory approvals to support potential commercialization worldwide.
Development programs in the Specialized BioTherapeutics segment also include expansion of synthetic hypericin (SGX302) into psoriasis, with top-line Phase 2a results anticipated. Additional pipeline candidates include the first-in-class innate defense regulator technology dusquetide (SGX942) for inflammatory diseases, including oral mucositis in head and neck cancer, and SGX945 in Behcet's Disease.
The company's Public Health Solutions business segment includes development programs for RiVax®, its ricin toxin vaccine candidate, along with vaccine programs targeting filoviruses such as Marburg and Ebola. This segment also includes CiVax™, the company's vaccine candidate for prevention of COVID-19 caused by SARS-CoV-2. These vaccine programs incorporate the proprietary heat stabilization platform technology ThermoVax® and have been supported with government grant and contract funding from multiple agencies including the National Institute of Allergy and Infectious Diseases (NIAID), the Defense Threat Reduction Agency (DTRA), and the Biomedical Advanced Research and Development Authority (BARDA).
Investors can access additional company information through the company's newsroom at https://ibn.fm/SNGX. The latest financial and clinical updates represent significant steps forward in addressing unmet medical needs across multiple rare disease categories, positioning the company for potential regulatory milestones and commercialization opportunities in the coming years.
